Recurrent or Metastatic Non-Squamous NSCLC – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036
- Published Date : June 18, 2026
- Updated On : September 3, 2026
- Pages : 154
Recurrent or Metastatic Non-Squamous NSCLC Market Outlook and Forecast
Thelansis’s “Recurrent or Metastatic Non-Squamous NSCLC Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Recurrent or Metastatic Non-Squamous NSCLC treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Recurrent or Metastatic Non-Squamous NSCLC Overview
Recurrent or metastatic non-squamous non-small cell lung cancer is an advanced thoracic malignancy characterized by substantial molecular and clinical heterogeneity. Management has evolved from chemotherapy-centered treatment toward biomarker-guided strategies, with targeted therapies used for actionable genomic alterations and immunotherapy-based regimens for tumors without actionable drivers. Current ASCO guidance recommends broad molecular testing, including comprehensive genomic profiling, to identify targetable alterations and guide treatment selection. Despite major advances, primary and acquired resistance, clonal evolution, heterogeneous target expression, and CNS progression continue to limit durable disease control. The therapeutic landscape is therefore expanding through complementary mechanisms rather than a single new class. ADCs are already entering clinical practice, including telisotuzumab vedotin for high c-MET-expressing nonsquamous NSCLC and datopotamab deruxtecan for previously treated EGFR-mutated NSCLC. In September 2026, sevabertinib also received accelerated FDA approval for HER2-mutated locally advanced or metastatic nonsquamous NSCLC, further expanding molecularly defined options. Meanwhile, next-generation ADCs, bispecific antibodies, and resistance-directed combinations remain active areas of development. For stakeholders, recurrent or metastatic nonsquamous NSCLC represents a high-value precision-oncology frontier where the central challenge is converting molecularly targeted responses into durable systemic and intracranial disease control despite evolving resistance.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal articles, third-party research databases)
Deliverables format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant support
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
Salient features of Market Forecast model:
- 10-year market forecast (2026–2036)
- Bottom-up patient-based market forecasts validated through the top-down sales methodology
- Covers clinically and commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and patient share?
- Which events will have the greatest impact on the market’s trajectory?
- What insights do interviewed experts provide on current and emerging treatments?
- Which pipeline products show the most promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for target profiles?
- What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
- and more…
Recurrent or Metastatic Non-Squamous NSCLC Market Outlook and Forecast
Thelansis’s “Recurrent or Metastatic Non-Squamous NSCLC Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Recurrent or Metastatic Non-Squamous NSCLC treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Recurrent or Metastatic Non-Squamous NSCLC Overview
Recurrent or metastatic non-squamous non-small cell lung cancer is an advanced thoracic malignancy characterized by substantial molecular and clinical heterogeneity. Management has evolved from chemotherapy-centered treatment toward biomarker-guided strategies, with targeted therapies used for actionable genomic alterations and immunotherapy-based regimens for tumors without actionable drivers. Current ASCO guidance recommends broad molecular testing, including comprehensive genomic profiling, to identify targetable alterations and guide treatment selection. Despite major advances, primary and acquired resistance, clonal evolution, heterogeneous target expression, and CNS progression continue to limit durable disease control. The therapeutic landscape is therefore expanding through complementary mechanisms rather than a single new class. ADCs are already entering clinical practice, including telisotuzumab vedotin for high c-MET-expressing nonsquamous NSCLC and datopotamab deruxtecan for previously treated EGFR-mutated NSCLC. In September 2026, sevabertinib also received accelerated FDA approval for HER2-mutated locally advanced or metastatic nonsquamous NSCLC, further expanding molecularly defined options. Meanwhile, next-generation ADCs, bispecific antibodies, and resistance-directed combinations remain active areas of development. For stakeholders, recurrent or metastatic nonsquamous NSCLC represents a high-value precision-oncology frontier where the central challenge is converting molecularly targeted responses into durable systemic and intracranial disease control despite evolving resistance.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal articles, third-party research databases)
Deliverables format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant support
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
Salient features of Market Forecast model:
- 10-year market forecast (2026–2036)
- Bottom-up patient-based market forecasts validated through the top-down sales methodology
- Covers clinically and commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and patient share?
- Which events will have the greatest impact on the market’s trajectory?
- What insights do interviewed experts provide on current and emerging treatments?
- Which pipeline products show the most promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for target profiles?
- What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
- and more…
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..
2. Disease Context
- Disease definition, classification, etiology and pathophysiology, drug targets,etc.
3. Epidemiology
- Key takeaways
- Incidence / Prevalence
- Diagnosed and Drug-Treated populations
- Comorbidities
- Other relevant patient segments
4. Market Size and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class specific trends
- Country-specific trends
5. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- Notable early-phase pipeline
6. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
Table of contents (TOC)
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..
2. Disease Context
- Disease definition, classification, etiology and pathophysiology, drug targets,etc.
3. Epidemiology
- Key takeaways
- Incidence / Prevalence
- Diagnosed and Drug-Treated populations
- Comorbidities
- Other relevant patient segments
4. Market Size and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class specific trends
- Country-specific trends
5. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- Notable early-phase pipeline
6. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)